Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 1,520,000 shares, an increase of 23.6% from the November 30th total of 1,230,000 shares. Based on an average daily trading volume, of 744,600 shares, the short-interest ratio is currently 2.0 days. Currently, 4.6% of the company's stock are sold short.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th.
Check Out Our Latest Research Report on HOWL
Werewolf Therapeutics Price Performance
HOWL remained flat at $1.48 during trading on Tuesday. 354,041 shares of the company traded hands, compared to its average volume of 424,043. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. Werewolf Therapeutics has a one year low of $1.38 and a one year high of $8.19. The firm's 50 day moving average price is $2.04 and its two-hundred day moving average price is $2.20.
Institutional Trading of Werewolf Therapeutics
Several hedge funds have recently made changes to their positions in HOWL. Walleye Capital LLC lifted its stake in shares of Werewolf Therapeutics by 10.7% during the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company's stock valued at $231,000 after buying an additional 10,528 shares in the last quarter. American Century Companies Inc. increased its position in shares of Werewolf Therapeutics by 50.7% in the second quarter. American Century Companies Inc. now owns 37,634 shares of the company's stock worth $92,000 after purchasing an additional 12,656 shares during the last quarter. SG Americas Securities LLC bought a new stake in Werewolf Therapeutics during the third quarter valued at approximately $29,000. Point72 DIFC Ltd purchased a new position in Werewolf Therapeutics in the 2nd quarter worth approximately $34,000. Finally, XTX Topco Ltd purchased a new stake in shares of Werewolf Therapeutics during the 3rd quarter valued at $45,000. 64.84% of the stock is currently owned by institutional investors.
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
See Also
Before you consider Werewolf Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.
While Werewolf Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
